Zoetis Inc (NYSE:ZTS) insider Roxanne Lagano sold 29,453 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $101.65, for a total value of $2,993,897.45. Following the transaction, the insider now owns 58,180 shares of the company’s stock, valued at $5,913,997. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Roxanne Lagano also recently made the following trade(s):
- On Monday, April 1st, Roxanne Lagano sold 2,000 shares of Zoetis stock. The stock was sold at an average price of $101.89, for a total value of $203,780.00.
Shares of ZTS stock opened at $101.84 on Thursday. The company has a market capitalization of $48.51 billion, a price-to-earnings ratio of 32.54, a price-to-earnings-growth ratio of 2.53 and a beta of 0.91. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $103.97.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.09. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.45 billion. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The company’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 earnings per share. On average, research analysts anticipate that Zoetis Inc will post 3.47 earnings per share for the current year.
ZTS has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Gabelli downgraded Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price for the company. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Credit Suisse Group lifted their target price on Zoetis from $102.00 to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, April 2nd. BMO Capital Markets lifted their target price on Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a report on Thursday, May 9th. Finally, UBS Group initiated coverage on Zoetis in a report on Wednesday, March 20th. They issued a “neutral” rating for the company. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $103.15.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dana Investment Advisors Inc. increased its holdings in shares of Zoetis by 6.9% during the first quarter. Dana Investment Advisors Inc. now owns 63,011 shares of the company’s stock valued at $6,343,000 after acquiring an additional 4,056 shares in the last quarter. Almanack Investment Partners LLC. increased its holdings in shares of Zoetis by 21.1% during the first quarter. Almanack Investment Partners LLC. now owns 3,163 shares of the company’s stock valued at $318,000 after acquiring an additional 552 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in shares of Zoetis by 6.9% during the first quarter. Massmutual Trust Co. FSB ADV now owns 25,766 shares of the company’s stock valued at $2,594,000 after acquiring an additional 1,652 shares in the last quarter. Natixis Advisors L.P. increased its holdings in shares of Zoetis by 5.0% during the first quarter. Natixis Advisors L.P. now owns 204,179 shares of the company’s stock valued at $20,555,000 after acquiring an additional 9,756 shares in the last quarter. Finally, Morgan Stanley increased its holdings in shares of Zoetis by 0.9% during the first quarter. Morgan Stanley now owns 13,785,853 shares of the company’s stock valued at $1,387,822,000 after acquiring an additional 127,988 shares in the last quarter. Hedge funds and other institutional investors own 90.78% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thestockobserver.com/2019/05/16/zoetis-inc-zts-insider-sells-2993897-45-in-stock.html.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Percentage Gainers
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.